Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia
- Auteur
- DARKOW, Theodore; HENK, Henry J; THOMAS, Simu K1 ; WEIWEI FENG2 ; BAIADI, Jean-Francois2 ; GOLDBERG, George A; HATFIELD, Alan2 ; CORTES, Jorge3
[1] Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States
[2] Novartis Pharmaceuticals Corporation, Florham Park, New Jersey, United States
[3] MD Anderson Cancer Center, Houston, Texas, United States - Source
PharmacoEconomics (Auckland). 2007, Vol 25, Num 6, pp 481-496, 16 p ; ref : 51 ref
- ISSN
- 1170-7690
- Domaine scientifique
- Hygiene and public health, epidemiology, occupational medicine; Pharmacology drugs
- Editeur
- Adis International, Auckland
- Pays de publication
- New Zealand
- Type de document
- Article
- Langue
- English
- Mot clé (fr)
- Analyse coût Anticancéreux Arrêt traitement Economie santé Etude longitudinale Homme Imatinib Inhibiteur enzyme Leucémie myéloïde Observance médicamenteuse Protein-tyrosine kinase Santé publique Soin intégré Inhibiteur de la tyrosine kinase Etats Unis Enzyme Hémopathie maligne Myéloprolifératif syndrome Transferases Amérique du Nord Amérique
- Mot clé (en)
- Cost analysis Antineoplastic agent Treatment withdrawal Health economy Follow up study Human Imatinib Enzyme inhibitor Chronic myelocytic leukemia Drug compliance Protein-tyrosine kinase Public health Managed care United States Enzyme Malignant hemopathy Myeloproliferative syndrome Transferases North America America
- Mot clé (es)
- Análisis costo Anticanceroso Paro tratamiento Economía salud Estudio longitudinal Hombre Imatinib Inhibidor enzima Leucemia mieloidea Observancia de la medicación Protein-tyrosine kinase Salud pública Cuidado integrado Estados Unidos Enzima Hemopatía maligna Mieloproliferativo síndrome Transferases America del norte America
- Classification
- Pascal
- 002 Sciences biologiques et medicales / 002B Sciences medicales / 002B02 Pharmacologie. Traitements medicamenteux / 002B02R Anticancéreux / 002B02R02 Chimiothérapie
- Pascal
- 002 Sciences biologiques et medicales / 002B Sciences medicales / 002B19 Hemopathies / 002B19B Leucémies. Lymphomes malins. Réticuloses malignes. Hématodermies. Splénomégalie myéloïde
- Discipline
- Blood diseases Pharmacological treatments
- Provenance
- Inist-CNRS
- Base de données
- PASCAL
- Identifiant INIST
- 18906591
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Accès au Document
Installer sur votre navigateur
DOI
10.2165/00019053-200725060-00004 
https://dx.doi.org/10.2165/00019053-200725060-00004
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00019053-200725060-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:28:\"PharmacoEconomics (Auckland)\";s:9:\"\u0000*\u0000stitle\";s:27:\"PharmacoEconomics (Auckl. )\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"481\";s:8:\"\u0000*\u0000epage\";s:3:\"496\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1170-7690\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"DARKOW\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Theodore\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"HENK, Henry J\";i:1;s:14:\"THOMAS, Simu K\";i:2;s:11:\"WEIWEI FENG\";i:3;s:21:\"BAIADI, Jean-Francois\";i:4;s:18:\"GOLDBERG, George A\";i:5;s:14:\"HATFIELD, Alan\";i:6;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Panist
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00019053-200725060-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:28:\"PharmacoEconomics (Auckland)\";s:9:\"\u0000*\u0000stitle\";s:27:\"PharmacoEconomics (Auckl. )\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"481\";s:8:\"\u0000*\u0000epage\";s:3:\"496\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1170-7690\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"DARKOW\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Theodore\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"HENK, Henry J\";i:1;s:14:\"THOMAS, Simu K\";i:2;s:11:\"WEIWEI FENG\";i:3;s:21:\"BAIADI, Jean-Francois\";i:4;s:18:\"GOLDBERG, George A\";i:5;s:14:\"HATFIELD, Alan\";i:6;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Istex
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00019053-200725060-00004\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Accès par Unpaywall
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00019053-200725060-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:28:\"PharmacoEconomics (Auckland)\";s:9:\"\u0000*\u0000stitle\";s:27:\"PharmacoEconomics (Auckl. )\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"481\";s:8:\"\u0000*\u0000epage\";s:3:\"496\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1170-7690\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"DARKOW\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Theodore\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"HENK, Henry J\";i:1;s:14:\"THOMAS, Simu K\";i:2;s:11:\"WEIWEI FENG\";i:3;s:21:\"BAIADI, Jean-Francois\";i:4;s:18:\"GOLDBERG, George A\";i:5;s:14:\"HATFIELD, Alan\";i:6;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par Europe PubMed Central
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00019053-200725060-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:9:\"\u0000*\u0000jtitle\";s:28:\"PharmacoEconomics (Auckland)\";s:9:\"\u0000*\u0000stitle\";s:27:\"PharmacoEconomics (Auckl. )\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:3:\"481\";s:8:\"\u0000*\u0000epage\";s:3:\"496\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1170-7690\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:6:\"DARKOW\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Theodore\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:7:{i:0;s:13:\"HENK, Henry J\";i:1;s:14:\"THOMAS, Simu K\";i:2;s:11:\"WEIWEI FENG\";i:3;s:21:\"BAIADI, Jean-Francois\";i:4;s:18:\"GOLDBERG, George A\";i:5;s:14:\"HATFIELD, Alan\";i:6;s:13:\"CORTES, Jorge\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:177:\"Treatment interruptions and non-adherence with imatinib and associated healthcare costs : A retrospective analysis among managed care patients with chronic myelogenous leukaemia\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"16\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Accès par arXiv
